Facebook
Twitter
LinkedIn
Forward
Gastrointestinal and Liver Manifestations of COVID-19
| Registration |
|---|
The HCV ECHO is a tele-mentoring program that uses videoconferencing technology (Zoom) to combine MAT didactic presentations with interactive and practical HCV case presentations from participants. To register, email ECHO@iowapca.org the following information: Name, title, credentials, organization name, and email address. |
Target Audience
Providers and clinical staff who are interested in providing treatment and care to individuals diagnosed with Hepatitis C (providers, nursing, behavioral health, linkage navigators, front desk/scheduling, admin, etc.).
Purpose
This interactive web-based program provides community-focused primary care clinicians an opportunity to become experts in the delivery of Hepatitis C care through a mentoring-based initiative. Project ECHO, developed by Dr. Sanjeev Aurora at the University of New Mexico (UNM) in 2003, provides a framework for sharing expertise across the state and as a result will help patients achieve a viral cure and avoid the downstream sequela associated with HCV without leaving the providers they trust and the communities where they live and work. Interested providers do not have to have any prior experience in treating Hepatitis C to participate in HCV ECHO.
The mission is to help centers and primary care providers manage HCV patients at their primary care center to alleviate barriers to care for un/underinsured patients by increasing the providers’ abilities to treat their patients at their primary care health center.
Professional Practice Gap
Iowa Medicaid requires medication treatment for HCV be prescribed by or in consult with a specialist. This creates a barrier to care for un/underinsured patients and a gap in care for patients and primary care providers that do not have access to specialists in their communities where specialists (infectious disease/hepatologists) are scarce or will only see a limited number of Medicaid patients.
The HCV ECHO will allow primary care providers to meet the prescribing requirement for Medicaid patients and to consult with specialists for all of their patients with HCV to allow the patients to be treated by their PCP at their local health center thus decreasing barriers to care and increasing positive health outcomes. The ECHO model allows for PCPs to increase their knowledge and skill set regarding Hepatitis C treatment and care through the didactic sessions and mentoring from specialists.
Learning Objectives
- Successfully diagnosis, manage, and treat patients with Hepatitis C.
- Manage HCV patients at their primary care center to alleviate barriers to care for un/underinsured patients by increasing the providers’ abilities to treat their patients at their primary care health center.
Agenda
| 11:45 am | Didactic Sessions Topics may include:
|
| 12:30 pm | Case Presentations You do not need to present a case during every session in order to participate in the HCV clinic. However, the submission of cases for presentation and discussion is a key component in the Project ECHO model and critically important for knowledge building and sharing, and it is therefore required that each provider present at minimum three cases per year. We welcome cases that involve common clinical scenarios related to HCV diagnosis and care as well as difficult, complex, or challenging presentations and patient management scenarios. |
HCV ECHO HUB TEAM
- Donald Hillebrand, MD, Medical Director, UnityPoint Health – Center for Liver Disease
- Steven Donnelly, PharmD, Community A Walgreens Specialty Pharmacy
- Mark Hillenbrand, LISW, RCSW, Authentic Freedom Counseling Center
- Megan Srinivas, MD, Infectious Disease, Community Health Centers of Fort Dodge
- Malissa S. Sprenger, MS, IAADC, Coordinator, Turning Point Treatment Center
ECHO COORDINATORS
- Julie Baker, MPA, CHCEF, Director of Preventive Services, Iowa Primary Care Association
- Faith Gachii, Executive Administrative Assistant, Iowa Primary Care Association
- Chelsea Miller, Administrative Assistant, Iowa Primary Care Association
Speaker
ROBERT G. GISH, MD, FAASLD began his medical training in 1974 when he was enrolled in the Pharmacy School at the University of Kansas. He transferred to the University of Kansas Medical School in 1977 and finished his MD degree in 1980.
Dr. Gish went on to complete a 3-year Internal Medicine residency at the University of California, San Diego and a 4-year Gastroenterology and Hepatology fellowship including transplant medicine at the University of California Los Angeles during which time he was awarded the NIH Physician Scientist Award to study calcium signaling in liver cells.
After completing his training, Dr. Gish moved to San Francisco and took a position at the California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital). He became the Co-Medical Director of the Liver Transplant Program in 1988 and then the Medical Director of the Liver Transplant Program in 1994 until 2010. In that role, he developed an outreach program that eventually served over 35,000 patients in the Northern California and Nevada regions and made the CPMC a leading liver transplant center.
Dr. Gish had and continues to have an active research program in viral hepatitis, liver transplant, bioartificial livers, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis. Although his primary research focus is clinical research, he frequently collaborates with basic scientists in his research activities. He has published more than 600 original articles, review articles, abstracts and book chapters.
Dr. Gish is also actively involved in numerous professional societies and is a long-term member of the American Association for the Study of Liver Disease, European Association for the Study of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society of Transplantation.
He is a fellow of both the American College of Physicians and the American Association for the Study of Liver Disease. Dr. Gish has served on the editorial boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of Viral Hepatitis among many others. He has co-authored a public health policy for liver health in Vietnam and is also assisting with the development of healthcare policies in Armenia and the Philippines.
In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical Professor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for Hepatobiliary Disease and Abdominal Transplantation (C.H.A.T.).
In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. Gish Consultants LLC to provide consultative support to Hepatology Centers and Liver Transplant Programs who wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education.
At that time, Dr. Gish joined Dr. Manch at St Joseph’s Hospital and Medical Center to start a liver transplant center and worked to establish a UNOS and Medicare certified program in 2016. Between April 2014 and June 2019, Dr. Gish served at Stanford’s Department of Medicine, Division of Gastroenterology and Hepatology and Liver Transplant Service Line as a Staff Physician with major roles with in-reach and outreach as well as program development.
Over the years of 2012 to current, Dr. Gish has been and continues to be very active with the National Viral Hepatitis Round Table (NVHR) a patient and community advocacy non-profit organization. In February of 2014, Dr. Gish joined the Hepatitis B Foundation, (HBF) as their Medical Director to lend his policy, advocacy and clinical science skills to their armamentarium.
Today, Dr. Gish is an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas, a Clinical Professor at the University of Nevada Reno School of Medicine, and a Clinical Professor at the University of California Skaggs School of Pharmacy and Pharmaceutical Sciences. In addition, he is also the Medical Director of the Hepatitis B Foundation and Medical Director of the Asian Pacific Health Foundation. Dr. Gish has joined the consulting faculty at La Maestra in San Diego to establish a liver care program in the Federally Qualified Health Care clinic.
Accreditation Statements
MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University 
(DMU) and the Iowa Primary Care Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live, online activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.5 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.5 continuing education contact hour(s). No partial credit awarded.
- Other Healthcare Professionals: This live activity is designated for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.
EDUCATIONAL GRANTS
No commercial interest company provided financial support for this continuing education activity.
DISCLOSURES
Relevant to the content of this educational activity, the following individuals have no conflicts of interest with commercial interest companies to disclose.
- Julie Baker, MPA, CHCEF
- Steven Donnelly, PharmD
- Faith Gachii
- Chelsea Miller
- Malissa S. Sprenger, MS, IAADC
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with commercial interest companies to disclose.
- Donald Hillebrand, MD, Speaker for AbbVie, Gilead, Merck, BMS, and Salix
- Mark Hillenbrand, LISW, RCSW, Spouse is a full-time employee at Vida Health
- Megan Srinivas, MD, Consultant (Self)
- Robert G. Gish, MD, FAASLD, View disclosures
The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
Available Credit
- 1.50 AMA PRA Category 1 Credits™
- 1.50 AOA Category 2A
- 1.50 CE Contact Hour(s)
- 1.50 IBON
Price
There is no cost to attend. Sessions are the third Tuesday of the month.
The HCV ECHO is a tele-mentoring program that uses videoconferencing technology (Zoom) to combine MAT didactic presentations with interactive and practical HCV case presentations from participants.
To register, email ECHO@iowapca.org the following information: Name, title, credentials, organization name, and email address.